Lonergan Partner is pleased to announce that Dan Rabinovitsj has joined the board of directors of Absci Corporation. This search was led by Mark Lonergan.
Since 2018, Dan has served as VP of Meta Connectivity, where he is focused on collaborating with industry partners to catalyze technology and business model innovations in the networking and telecommunications industries to realize both structural opex and capex reductions for service providers and performance enhancements to enable the metaverse. Prior to Meta, he served as President and COO of Ruckus Networks, where he focused on delivering high performance wireless and wired connectivity in the Enterprise and Service Provider markets. He has held executive leadership roles at Silicon Labs, NXP, Atheros and Qualcomm.
With three decades of leadership in scaling technologies, innovating business models and growing companies, Dan will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster.
This appointment comes during a time of strategic evolution for Absci, which is deploying more than a decade of experience in synthetic biology to dramatically power its generative AI-powered drug creation capabilities. Dan will join Absci’s Board of Directors following Dr. Andreas Busch’s transition from an Absci’s Board member to his current role as Absci’s Chief Innovation Officer. Dr. Busch’s track record of bringing over 10 drug candidates to market, along with Dan's expertise in growing and innovating business models will further strengthen Absci’s ability to deliver on its vision.
“Dan is a proven leader who has scaled technologies that take businesses to new heights and unlock new ecosystems,” said Sean McClain, Founder and CEO of Absci. “He has been a key player in helping Meta build out strategy and technology. With the convergence of the technology and biotech industries, now more than ever, Dan’s experience and insights will be invaluable in our mission to create better biologics, faster.”
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™.
Absci has impressed me with their technology and data, together which have the potential to turn Absci’s bold vision into reality: to create therapeutics at a click of a button. Absci stands out in a complex market with its ability to combine cutting-edge generative AI models with proprietary wet-lab capabilities for real-time validation. It’s no surprise that the company has a growing pipeline of industry-leading partnerships, and I look forward to teaming up with them to achieve their ambitious goals.Dan Rabinovitsj, Board Director, Absci
Absci is reinventing the drug discovery market, using High Performance Computing to deliver new drug compounds. Dan is an ideal addition to the Absci board, being a Renaissance businessman with an incredible appetite for new technologies.Mark Lonergan, Founder & Operating Partner, Lonergan Partners